Edward J. Quinlan, MD

Ophthalmologist

Specialties: Retina

Edward J. Quinlan, M.D. graduated from the University of Nebraska Medical Center in 1994. He completed his Ophthalmology residency at West Virginia University Medical Center and a 2 year Vitreoretinal fellowship at the Wilmer Eye Institute of the Johns Hopkins Hospitals in Baltimore, Maryland. Dr. Quinlan was on the faculty of the Wilmer Eye Institute as an Assistant Professor of Ophthalmology from 2002-2007

Published journals:

2018 Clinical Trials

Investigator

• Kodiak – Phase I Open Label, Multicenter Study
  Ocular and systemic safety, tolerability, and pharmacokinetics of a single intravitreal administration of KSI-301 in subjects with center-involved diabetic macular edema (DME).

• Chengdu Kanghong Biotechnology (PANDA) – Multicenter, Double-Masked, Randomized, Dose-Ranging Trial
  Evaluating efficacy and safety of Conbercept intravitreal injection for neovascular age-related macular degeneration (AMD).

• Genentech Roche (RHINE) – Phase III, Multicenter, Randomized, Double-Masked Trial
  Efficacy and safety of RO6867461 in diabetic macular edema.

• Genentech Roche (LADDER EXT) – Open-Label Extension Study
  Long-term safety and tolerability of the port delivery system with ranibizumab in neovascular AMD.

• Novartis (KESTREL) – Phase III, Randomized, Double-Masked Trial
  Comparing Brolucizumab vs. Aflibercept for diabetic macular edema.

• Novartis (MERLIN) – Phase 3a Randomized, Double-Masked Study
  Brolucizumab vs. Aflibercept in nAMD patients with persistent fluid.

• Reneuron Ltd – Phase I/IIa, First-in-Human Study
  Subretinal transplantation of human retinal progenitor cells (hRPC) in retinitis pigmentosa.

• Santen Philippines Inc. (AVANTE) – Phase II, Multicenter, Randomized, Double-Masked Study
  Intravitreal DE-122 + Lucentis vs. Lucentis monotherapy in wet AMD.

• Genentech (ARCHWAY) – Phase III Evaluation
  Efficacy, safety, and pharmacokinetics of ranibizumab via port delivery system in nAMD.

• Apellis (DERBY) – Phase III, Randomized, Sham-Controlled Study
  Intravitreal APL-2 therapy in geographic atrophy secondary to AMD.

• Mallinckrodt – Pilot Study
  Efficacy and safety of H.P. Acthar® Gel in noninfectious intermediate, posterior uveitis, or panuveitis.

• Aerie Pharmaceuticals – Open-Label, Proof-of-Concept Study
  AR-1105 in macular edema due to retinal vein occlusion.

• BeyeOnics – Prospective Single-Center Study
  Safety and performance of AR Video Microscope in ophthalmic surgery.

• Thrombogenics – Phase I, Dose-Escalation Study
  THR-149 for diabetic macular edema.

• Opthea – Phase 1B/2A Study
  OPT302 with Aflibercept for persistent DME.

• DigiSight Technologies (CLEAR) – Prospective, Single-Arm Study
  Paxos Checkup mobile app correlation to standard in-office assessments.

• Ophthotech

  • Phase 2A Open-Label Trial – Zimura + Lucentis in treatment-naïve nAMD.

  • Phase 2/3 Randomized Trial – Zimura for geographic atrophy due to dry AMD.

  • Phase 2b Randomized Trial – Zimura in autosomal recessive Stargardt disease.

• Aerpio – Phase 2 Double-Masked, Placebo-Controlled Study
  AKB-9778 in moderate to severe NPDR.

• Allegro – Phase II, Double-Masked Crossover Trial
  1.0 mg Luminate (ALG-1001) for non-exudative AMD.

• Clearside – Randomized, Masked, Controlled Trial
  Suprachoroidal CLS-TA + anti-VEGF vs. anti-VEGF monotherapy in RVO.

2017 Retinal Research Studies

Co-Investigator

• Genentech (STAIRWAY) – Phase II Trial
  RO6867461 dosing intervals in choroidal neovascularization.

• DigiSight (CLEAR DS2001) – Mobile App Assessment Study
  Paxos Checkup mobile app vs. standard visual assessments.

• VisionCare (IMT-TES 2016) – Miniature Telescope Study
  Implantable device in pseudophakic patients with end-stage AMD.

• Taiwan Liposome Company (TLC399A2002) – Phase IIa, Randomized Trial
  Liposomal steroid injection for CRVO-related macular edema.

• Clearside (MAGNOLIA) – Uveitis Extension Study
  Safety and efficacy of CLS-TA.

• Aldeyra (ADX-102) – Phase 3 Trial
  Topical ocular formulation for non-infectious anterior uveitis.

• Clearside (SAPPHIRE) – Phase III Controlled Trial
  CLS-TA with anti-VEGF for CRVO/BRVO patients.

• Allergan (SAPLING) – Phase I Study
  Abicipar Pegol pharmacokinetics in nAMD.

• Clearside (AZALEA) – Open-Label Safety Study
  Suprachoroidal triamcinolone in uveitis.

• USC (OCT Angiography & Diabetes Study) – OCTA and Standard Imaging Comparison
  Diabetic patients imaged with Zeiss 7-field and OCTA.

• Santhera (SNT-IV-005) – Intervention Study
  Long-term Raxone treatment for Leber’s Hereditary Optic Neuropathy.

• Aerpio (AKB-9778-CI-5001) – Phase 2 Study
  AKB-9778 for moderate to severe NPDR.

• Greybug Vision (ADAGIO) – Phase I/II Study
  Intravitreal depot GB-102 in nAMD.

• Allegro (DRY AMD 101) – Exploratory Trial
  Luminate for non-exudative AMD.

• Clearside (TYBEE) – Controlled Trial
  CLS-TA + Aflibercept vs. Aflibercept alone in DME.

• USC (RPT-14-01) – Phase I/IIA Safety Study
  CPCB-RPE1 stem cell implant for advanced dry AMD.

• Ophthotech (OPH2007) – Phase 2A Trial
  Zimura + Lucentis for treatment-naïve nAMD.

• Opthea (OPT302-1002) – Dose Ranging Study
  OPT-302 + Ranibizumab vs. Ranibizumab alone in nAMD.

Honors:

• American Society of Retinal Specialists

• Association for Research in Vision and Ophthalmology

Achievements:

Dr. Quinlan served as a principal investigator and co-investigator in numerous clinical trials. His research focused on emerging treatments for retinal diseases, including age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. These studies encompassed a wide range of innovative therapies such as anti-VEGF agents, gene therapy, stem cell transplantation, and sustained drug delivery systems. His involvement contributed to the advancement of sight-saving treatments and has supported multiple peer-reviewed publications and FDA submissions.